Doximity Q2 2027: Revenue and EPS Beat, but AI Costs Bite

As seen on the 24/7 Wall St. homepage on November 5, 2026.

DOCS Doximity
Q2 2027
EPS
$0.36
est $0.35 +2.8%
Revenue
$175M
est $170M +2.5%

Doximity beat on both lines and raised full-year revenue guidance to $678 million to $683 million, but the AI buildout is eating the margin: adjusted EBITDA fell 12%. Management says more than 190 health systems have bought the AI suite, which is the number that has to justify the spending.

Continue ReadingShow less

Doximity delivered fiscal second-quarter revenue of $174.5 million, beating expectations, with adjusted non-GAAP EPS of $0.36 also clearing estimates.

Higher cost of revenue compressed GAAP gross margin to 85.5% from 90.3%, and adjusted EBITDA fell 12% to $88.86 million. That is a meaningful step down for a company built on lean operations.

The spending reflects an aggressive push into artificial intelligence, with R&D expense rising to $41.96 million. CEO Jeff Tangney said more than 190 health systems have now purchased the AI suite, including Ask, Scribe, PeerCheck, and DoseCheck. That adoption figure shows whether the margin sacrifice is converting into durable customer expansion.

Sponsored

Tangney cited record platform engagement, though GAAP net income fell 44% year over year to $34.73 million and operating income dropped 31%. Free cash flow stayed essentially flat at $91.33 million, so the cash engine remains intact through the investment cycle.

Doximity raised full-year fiscal 2027 revenue guidance to $678 million to $683 million. The quarter also unfolded alongside ongoing securities class action litigation alleging past misstatements about revenue growth, a backdrop for investors monitoring the stock.

Mentioned: DOCS